Vertex Pharma's Q1 2026: Strong Earnings & Renal Expansion

Vertex Pharmaceuticals Q1 2026 earnings showcase robust growth, with $2.99 billion in product revenue, an 8% increase from last year. Key drivers include AlifTracks $1 billion in sales, Kasjevis 500 patients, and Jernavixs 1 million prescriptions. R&D advancements in kidney disease, such as Povis phase three data in IgAN, propel growth. The CF franchise expanded by 6% globally, and non-GAAP EPS reached $4.47, up from $4.06. Vertex remains committed to full-year revenue guidance and pipeline expansion into renal disease. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/2df037b594607513